BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med. 2011;183:1231-1237. [PMID: 21131468 DOI: 10.1164/rccm.201007-1179oc] [Cited by in Crossref: 247] [Cited by in F6Publishing: 92] [Article Influence: 20.6] [Reference Citation Analysis]
Number Citing Articles
1 Hirabayashi R, Takahashi Y, Nagata K, Morimoto T, Wakata K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K. The validity and reliability of four-meter gait speed test for stable interstitial lung disease patients: the prospective study. J Thorac Dis 2020;12:1296-304. [PMID: 32395266 DOI: 10.21037/jtd.2020.02.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, Maddens S, Rizzo S, Kirchgaessler K, Bartley K, Bondue B. Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry. Pulm Ther. [DOI: 10.1007/s41030-022-00187-8] [Reference Citation Analysis]
3 Gong SG, Wang L, Pudasaini B, Yuan P, Jiang R, Zhao QH, He J, Zhang R, Wu WH, Liu JM, Zhou CC. Transition from Ambrisentan to Bosentan in Pulmonary Arterial Hypertension: A Single-Center Prospective Study. Can Respir J 2018;2018:9836820. [PMID: 29849836 DOI: 10.1155/2018/9836820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Sharp C, Adamali HI, Millar AB. A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis. ERJ Open Res 2017;3:00096-2016. [PMID: 28326312 DOI: 10.1183/23120541.00096-2016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
5 Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int 2015;2015:329481. [PMID: 26779535 DOI: 10.1155/2015/329481] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
6 Swigris J, Olson AL, Brown K. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. PROM. [DOI: 10.2147/prom.s74857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
7 El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Peters E, Haughey M, Bienfang D, Jones AM, Julien-Williams P, Cui Y, Villalba JA, Bagwe S, Maurer R, Rosas IO, Moss J, Henske EP. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest 2017;151:1302-10. [PMID: 28192114 DOI: 10.1016/j.chest.2017.01.033] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
8 Nathan SD. Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat? Thorax 2014;69:107-8. [DOI: 10.1136/thoraxjnl-2013-204964] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Kulkarni T, Valentine VG, Fei F, Tran-Nguyen TK, Quesada-Arias LD, Mkorombindo T, Pham HP, Simmons SC, Dsouza KG, Luckhardt T, Duncan SR. Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations. PLoS One 2021;16:e0260345. [PMID: 34813613 DOI: 10.1371/journal.pone.0260345] [Reference Citation Analysis]
10 Campo M, Oursler KK, Huang L, Goetz MB, Rimland D, Hoo GS, Brown ST, Rodriguez-Barradas MC, Au D, Akgün KM, Shahrir S, Crothers K. Association of chronic cough and pulmonary function with 6-minute walk test performance in HIV infection. J Acquir Immune Defic Syndr 2014;65:557-63. [PMID: 24346638 DOI: 10.1097/QAI.0000000000000086] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
11 Pitre T, Mah J, Helmeczi W, Khalid MF, Cui S, Zhang M, Husnudinov R, Su J, Banfield L, Guy B, Coyne J, Scallan C, Kolb MR, Jones A, Zeraatkar D. Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax 2022:thoraxjnl-2021-217976. [PMID: 35145039 DOI: 10.1136/thoraxjnl-2021-217976] [Reference Citation Analysis]
12 Nunes FS, Pastre J, Brown AW, Shlobin OA, King C, Weir NA, Nathan SD. Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis? Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021005. [PMID: 33867792 DOI: 10.36141/svdld.v38i1.9258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Martínez González C, González Barcala FJ, Belda Ramírez J, González Ros I, Alfageme Michavila I, Orejas Martínez C, González Rodríguez-Moro JM, Rodríguez Portal JA, Fernández Álvarez R; Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Recommendations for fitness for work medical evaluations in chronic respiratory patients. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2013;49:480-90. [PMID: 24120308 DOI: 10.1016/j.arbres.2013.06.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2016;194:711-8. [PMID: 26938706 DOI: 10.1164/rccm.201508-1546OC] [Cited by in Crossref: 51] [Cited by in F6Publishing: 23] [Article Influence: 10.2] [Reference Citation Analysis]
15 Machado FVC, Bloem AEM, Schneeberger T, Jarosch I, Gloeckl R, Winterkamp S, Franssen FME, Koczulla AR, Pitta F, Spruit MA, Kenn K. Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis. BMJ Open Respir Res 2021;8:e001039. [PMID: 34711642 DOI: 10.1136/bmjresp-2021-001039] [Reference Citation Analysis]
16 Weill D. Lung transplantation: indications and contraindications. J Thorac Dis 2018;10:4574-87. [PMID: 30174910 DOI: 10.21037/jtd.2018.06.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
17 Gupta R, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine 2022;196:106801. [DOI: 10.1016/j.rmed.2022.106801] [Reference Citation Analysis]
18 Cerdán-de-Las-Heras J, Balbino F, Løkke A, Catalán-Matamoros D, Hilberg O, Bendstrup E. Tele-Rehabilitation Program in Idiopathic Pulmonary Fibrosis-A Single-Center Randomized Trial. Int J Environ Res Public Health 2021;18:10016. [PMID: 34639313 DOI: 10.3390/ijerph181910016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Caffrey D, Miranda JJ, Gilman RH, Davila-Roman VG, Cabrera L, Dowling R, Stewart T, Bernabe-Ortiz A, Wise R, Leon-Velarde F, Checkley W; CRONICAS Cohort Study Group. A cross-sectional study of differences in 6-min walk distance in healthy adults residing at high altitude versus sea level. Extrem Physiol Med 2014;3:3. [PMID: 24484777 DOI: 10.1186/2046-7648-3-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Someya F, Nakagawa T, Mugii N. The COPD Assessment Test as a Prognostic Marker in Interstitial Lung Disease. Clin Med Insights Circ Respir Pulm Med 2016;10:27-31. [PMID: 27812295 DOI: 10.4137/CCRPM.S40792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Someya F, Mugii N. Limitations to the 6-minute walk test in dermatomyositis with interstitial lung disease in comparison with idiopathic interstitial pneumonia. Clin Med Insights Circ Respir Pulm Med 2013;7:1-6. [PMID: 23400027 DOI: 10.4137/CCRPM.S10764] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Hanada M, Kasawara KT, Mathur S, Rozenberg D, Kozu R, Hassan SA, Reid WD. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J Thorac Dis 2020;12:1041-55. [PMID: 32274173 DOI: 10.21037/jtd.2019.12.27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
23 Nakamura Y, Suda T. Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med 2015;9:163-71. [PMID: 27625576 DOI: 10.4137/CCRPM.S39897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
24 Shen Q, Guo T, Song M, Guo W, Zhang Y, Duan W, Peng Y, Ni S, Ouyang X, Peng H. Pain is a common problem in patients with ILD. Respir Res 2020;21:297. [PMID: 33176795 DOI: 10.1186/s12931-020-01564-0] [Reference Citation Analysis]
25 Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A. Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respir Res 2019;20:47. [PMID: 30823880 DOI: 10.1186/s12931-019-1010-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
26 Luckhardt TR, Müller-Quernheim J, Thannickal VJ. Update in diffuse parenchymal lung disease 2011. Am J Respir Crit Care Med 2012;186:24-9. [PMID: 22753686 DOI: 10.1164/rccm.201203-0509UP] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Hung M, Baumhauer JF, Licari FW, Voss MW, Bounsanga J, Saltzman CL. PROMIS and FAAM Minimal Clinically Important Differences in Foot and Ankle Orthopedics. Foot Ankle Int 2019;40:65-73. [PMID: 30282469 DOI: 10.1177/1071100718800304] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
28 Nurek M, Rayner C, Freyer A, Taylor S, Järte L, MacDermott N, Delaney BC; Delphi panellists. Recommendations for the recognition, diagnosis, and management of long COVID: a Delphi study. Br J Gen Pract 2021;71:e815-25. [PMID: 34607799 DOI: 10.3399/BJGP.2021.0265] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med 2014;108:819-29. [PMID: 24746629 DOI: 10.1016/j.rmed.2014.03.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
30 Mathai SC, Puhan MA, Lam D, Wise RA. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:428-33. [PMID: 22723290 DOI: 10.1164/rccm.201203-0480OC] [Cited by in Crossref: 150] [Cited by in F6Publishing: 52] [Article Influence: 15.0] [Reference Citation Analysis]
31 Lachmann R, Schoser B. The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 2013;8:160. [PMID: 24119230 DOI: 10.1186/1750-1172-8-160] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
32 Kaleth AS, Slaven JE, Ang DC. Determining the Minimal Clinically Important Difference for 6-Minute Walk Distance in Fibromyalgia. Am J Phys Med Rehabil 2016;95:738-45. [PMID: 27003201 DOI: 10.1097/PHM.0000000000000485] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
33 Cox NS, McDonald CF, Alison JA, Mahal A, Wootton R, Hill CJ, Bondarenko J, Macdonald H, O'Halloran P, Zanaboni P, Clarke K, Rennick D, Borgelt K, Burge AT, Lahham A, Wageck B, Crute H, Czupryn P, Nichols A, Holland AE. Telerehabilitation versus traditional centre-based pulmonary rehabilitation for people with chronic respiratory disease: protocol for a randomised controlled trial. BMC Pulm Med 2018;18:71. [PMID: 29764393 DOI: 10.1186/s12890-018-0646-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
34 Perez-Bogerd S, Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, Troosters T. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res 2018;19:182. [PMID: 30236104 DOI: 10.1186/s12931-018-0884-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
35 Skandamis A, Kani C, Markantonis SL, Souliotis K. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J Drug Assess 2019;8:55-61. [PMID: 31044096 DOI: 10.1080/21556660.2019.1597726] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
36 Lin CY, Hsieh MH, Fang YF, Peng CW, Ju JS, Lo YL, Lin SM, Lin HC. Predicting mortality in non-cystic fibrosis bronchiectasis patients using distance-saturation product. Ann Med 2021;53:2034-40. [PMID: 34761709 DOI: 10.1080/07853890.2021.1999490] [Reference Citation Analysis]
37 Coker RK, Armstrong A, Church AC, Holmes S, Naylor J, Pike K, Saunders P, Spurling KJ, Vaughn P. BTS Clinical Statement on air travel for passengers with respiratory disease. Thorax. [DOI: 10.1136/thoraxjnl-2021-218110] [Reference Citation Analysis]
38 Christiansen CL, Fields T, Lev G, Stephenson RO, Stevens-Lapsley JE. Functional Outcomes After the Prosthetic Training Phase of Rehabilitation After Dysvascular Lower Extremity Amputation. PM R 2015;7:1118-26. [PMID: 25978948 DOI: 10.1016/j.pmrj.2015.05.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
39 Gochicoa-Rangel L, Ramírez-José MC, Troncoso-Huitrón P, Silva-Cerón M, Guzmán-Valderrábano C, Lechuga-Trejo I, Cid-Juárez S, Torre-Bouscoulet L. Shorter corridors can be used for the six-minute walk test in subjects with chronic lung diseases. Respir Investig 2020;58:255-61. [PMID: 32111517 DOI: 10.1016/j.resinv.2019.12.009] [Reference Citation Analysis]
40 Cantarero-Villanueva I, Postigo-Martin P, Granger CL, Waterland J, Galiano-Castillo N, Denehy L. The minimal clinically important difference in the treadmill six-minute walk test in active women with breast cancer during and after oncological treatments. Disabil Rehabil 2022;:1-8. [PMID: 35352996 DOI: 10.1080/09638288.2022.2043461] [Reference Citation Analysis]
41 Porteous MK, Rivera-Lebron BN, Kreider M, Lee J, Kawut SM. Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation. Pulm Circ 2016;6:30-6. [PMID: 27076905 DOI: 10.1086/685022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
42 Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest 2012;142:291-7. [PMID: 22871754 DOI: 10.1378/chest.11-2602] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
43 Repac J, Alvarez LX, Lamb K, Gillette RL. Evaluation of Thermographic Imaging in Canine Hindlimb Muscles After 6 Min of Walking-A Pilot Study. Front Vet Sci 2020;7:224. [PMID: 32426382 DOI: 10.3389/fvets.2020.00224] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ; IPFnet Investigators. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. Chest 2013;143:1699-708. [PMID: 23732584 DOI: 10.1378/chest.12-1594] [Cited by in Crossref: 130] [Cited by in F6Publishing: 103] [Article Influence: 14.4] [Reference Citation Analysis]
45 Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 2013;64:407-25. [PMID: 23215857 DOI: 10.1146/annurev-med-120611-144851] [Cited by in Crossref: 128] [Cited by in F6Publishing: 101] [Article Influence: 12.8] [Reference Citation Analysis]
46 Yu X, Li X, Wang L, Liu R, Xie Y, Li S, Li J. Pulmonary Rehabilitation for Exercise Tolerance and Quality of Life in IPF Patients: A Systematic Review and Meta-Analysis. Biomed Res Int 2019;2019:8498603. [PMID: 31016200 DOI: 10.1155/2019/8498603] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
47 Pruitt B. Idiopathic pulmonary fibrosis: What nurses need to know. Nursing 2021;51:22-9. [PMID: 33346613 DOI: 10.1097/01.NURSE.0000724352.48335.1b] [Reference Citation Analysis]
48 Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med 2014;20:463-71. [PMID: 25022315 DOI: 10.1097/MCP.0000000000000091] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 5.9] [Reference Citation Analysis]
49 Ho SC, Lin HC, Kuo HP, Chen LF, Sheng TF, Jao WC, Wang CH, Lee KY. Exercise training with negative pressure ventilation improves exercise capacity in patients with severe restrictive lung disease: a prospective controlled study. Respir Res 2013;14:22. [PMID: 23421438 DOI: 10.1186/1465-9921-14-22] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
50 Meyer KC. Diagnosis and management of interstitial lung disease. Transl Respir Med 2014;2:4. [PMID: 25505696 DOI: 10.1186/2213-0802-2-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 52] [Article Influence: 8.6] [Reference Citation Analysis]
51 Chandel A, Pastre J, Valery S, King CS, Nathan SD. Derivation and validation of a simple multidimensional index incorporating exercise capacity parameters for survival prediction in idiopathic pulmonary fibrosis. Thorax 2022:thoraxjnl-2021-218440. [PMID: 35332096 DOI: 10.1136/thoraxjnl-2021-218440] [Reference Citation Analysis]
52 Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H. Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulm Med 2017;17:104. [PMID: 28743305 DOI: 10.1186/s12890-017-0444-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
53 Molgat-Seon Y, Schaeffer MR, Ryerson CJ, Guenette JA. Cardiopulmonary Exercise Testing in Patients With Interstitial Lung Disease. Front Physiol 2020;11:832. [PMID: 32754054 DOI: 10.3389/fphys.2020.00832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Fernández Fabrellas E, Peris Sánchez R, Sabater Abad C, Juan Samper G. Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis. Med Sci (Basel) 2018;6:E51. [PMID: 29904028 DOI: 10.3390/medsci6020051] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
55 Rhinehart JD, Schober KE, Scansen BA, Yildiz V, Bonagura JD. Effect of Body Position, Exercise, and Sedation on Estimation of Pulmonary Artery Pressure in Dogs with Degenerative Atrioventricular Valve Disease. J Vet Intern Med 2017;31:1611-21. [PMID: 28865107 DOI: 10.1111/jvim.14814] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
56 Lei S, Li X, Xie Y, Li J. Clinical evidence for improving exercise tolerance and quality of life with pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Clin Rehabil 2022;:2692155221095481. [PMID: 35481421 DOI: 10.1177/02692155221095481] [Reference Citation Analysis]
57 Kang M, Veeraraghavan S, Martin GS, Kempker JA. An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis. ERJ Open Res 2021;7:00142-2021. [PMID: 34671666 DOI: 10.1183/23120541.00142-2021] [Reference Citation Analysis]
58 Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, Bouros D, Glassberg MK. Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2018;5:142. [PMID: 29868594 DOI: 10.3389/fmed.2018.00142] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
59 Majewski S, Szewczyk K, Żal A, Białas AJ, Miłkowska-Dymanowska J, Piotrowski WJ. Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study. J Clin Med 2021;10:3864. [PMID: 34501312 DOI: 10.3390/jcm10173864] [Reference Citation Analysis]
60 Ramadurai D, Riordan M, Graney B, Churney T, Olson AL, Swigris JJ. The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease. Respir Med 2018;138:32-7. [PMID: 29724390 DOI: 10.1016/j.rmed.2018.03.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
61 Karanth MS, Awad NT. Six Minute Walk Test: A Tool for Predicting Mortality in Chronic Pulmonary Diseases. J Clin Diagn Res 2017;11:OC34-8. [PMID: 28571188 DOI: 10.7860/JCDR/2017/24707.9723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
62 Eves ND, Koelwyn GJ. Short of breath, short of benefit: important considerations for the rehabilitation of IPF patients. Respirology 2011;16:1163-4. [PMID: 21883682 DOI: 10.1111/j.1440-1843.2011.02055.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
63 Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012;185:1147-53. [PMID: 22366047 DOI: 10.1164/rccm.201108-1420PP] [Cited by in Crossref: 92] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
64 Doyle TJ, Washko GR, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Divo MJ, Celli BR, Sciurba FC, Silverman EK, Hatabu H, Rosas IO, Hunninghake GM; COPDGene Investigators. Interstitial lung abnormalities and reduced exercise capacity. Am J Respir Crit Care Med 2012;185:756-62. [PMID: 22268134 DOI: 10.1164/rccm.201109-1618OC] [Cited by in Crossref: 71] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
65 Nöhre M, Paslakis G, Albayrak Ö, Bauer-Hohmann M, Brederecke J, Eser-Valeri D, Tudorache I, de Zwaan M. Factor Analyses and Validity of the Transplant Evaluation Rating Scale (TERS) in a Large Sample of Lung Transplant Candidates. Front Psychiatry 2020;11:373. [PMID: 32425836 DOI: 10.3389/fpsyt.2020.00373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Alhamad EH, Cal JG. Predictors of mortality in interstitial lung disease patients without pulmonary hypertension. Ann Thorac Med 2020;15:238-43. [PMID: 33381239 DOI: 10.4103/atm.ATM_438_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2015;11:359-70. [PMID: 25767391 DOI: 10.2147/TCRM.S69716] [Cited by in Crossref: 10] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
68 Pesonen I, Gao J, Kalafatis D, Carlson L, Sköld M, Ferrara G. Six-minute walking test outweighs other predictors of mortality in idiopathic pulmonary fibrosis. A real-life study from the Swedish IPF registry. Respiratory Medicine: X 2020;2:100017. [DOI: 10.1016/j.yrmex.2020.100017] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 Hong SH, Yang HI, Kim DI, Gonzales TI, Brage S, Jeon JY. Validation of Submaximal Step Tests and the 6-Min Walk Test for Predicting Maximal Oxygen Consumption in Young and Healthy Participants. Int J Environ Res Public Health 2019;16:E4858. [PMID: 31816834 DOI: 10.3390/ijerph16234858] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
70 Russo P, Tomino C, Santoro A, Prinzi G, Proietti S, Kisialiou A, Cardaci V, Fini M, Magnani M, Collacchi F, Provinciali M, Giacconi R, Bonassi S, Malavolta M. FKBP5 rs4713916: A Potential Genetic Predictor of Interindividual Different Response to Inhaled Corticosteroids in Patients with Chronic Obstructive Pulmonary Disease in a Real-Life Setting. Int J Mol Sci 2019;20:E2024. [PMID: 31022961 DOI: 10.3390/ijms20082024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
71 Chen T, Tsai APY, Hur SA, Wong AW, Sadatsafavi M, Fisher JH, Johannson KA, Assayag D, Morisset J, Shapera S, Khalil N, Fell CD, Manganas H, Cox G, To T, Gershon AS, Hambly N, Halayko AJ, Wilcox PG, Kolb M, Ryerson CJ. Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respir Res 2021;22:202. [PMID: 34238283 DOI: 10.1186/s12931-021-01790-0] [Reference Citation Analysis]
72 Ussavarungsi K, Lee AS, Burger CD. Can a Six-Minute Walk Distance Predict Right Ventricular Dysfunction in Patients with Diffuse Parenchymal Lung Disease and Pulmonary Hypertension? Oman Med J 2016;31:345-51. [PMID: 27602188 DOI: 10.5001/omj.2016.69] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, Cederholm T, Coats AJ, Cummings SR, Evans WJ, Fearon K, Ferrucci L, Fielding RA, Guralnik JM, Harris TB, Inui A, Kalantar-Zadeh K, Kirwan BA, Mantovani G, Muscaritoli M, Newman AB, Rossi-Fanelli F, Rosano GM, Roubenoff R, Schambelan M, Sokol GH, Storer TW, Vellas B, von Haehling S, Yeh SS, Anker SD; Society on Sarcopenia, Cachexia and Wasting Disorders Trialist Workshop. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 2011;12:403-9. [PMID: 21640657 DOI: 10.1016/j.jamda.2011.04.014] [Cited by in Crossref: 617] [Cited by in F6Publishing: 533] [Article Influence: 56.1] [Reference Citation Analysis]
74 Raghu G, Collard HR, Anstrom KJ, Flaherty KR, Fleming TR, King TE Jr, Martinez FJ, Brown KK. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012;185:1044-8. [PMID: 22505745 DOI: 10.1164/rccm.201201-0006PP] [Cited by in Crossref: 155] [Cited by in F6Publishing: 60] [Article Influence: 15.5] [Reference Citation Analysis]
75 Jackson RM, Gómez-Marín OW, Ramos CF, Sol CM, Cohen MI, Gaunaurd IA, Cahalin LP, Cardenas DD. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung 2014;192:367-76. [PMID: 24705678 DOI: 10.1007/s00408-014-9566-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
76 Alexandre HF, Cani KC, Araújo J, Mayer AF. Reliability and validity of the Glittre-ADL test to assess the functional status of patients with interstitial lung disease. Chron Respir Dis 2021;18:14799731211012962. [PMID: 34219497 DOI: 10.1177/14799731211012962] [Reference Citation Analysis]
77 Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012;126:349-56. [PMID: 22696079 DOI: 10.1161/CIRCULATIONAHA.112.105890] [Cited by in Crossref: 152] [Cited by in F6Publishing: 60] [Article Influence: 15.2] [Reference Citation Analysis]
78 Mancuzo EV, Soares MR, Pereira CAC. Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil. J Bras Pneumol 2018;44:267-72. [PMID: 30328926 DOI: 10.1590/S1806-37562018000000049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, Glanzman AM, Spiegel R, Barth J, Elfring G, Reha A, Peltz SW; PTC124-GD-007-DMD Study Group. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 2013;48:357-68. [PMID: 23674289 DOI: 10.1002/mus.23905] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 17.3] [Reference Citation Analysis]
80 Castleberry AW, Englum BR, Snyder LD, Worni M, Osho AA, Gulack BC, Palmer SM, Davis RD, Hartwig MG. The utility of preoperative six-minute-walk distance in lung transplantation. Am J Respir Crit Care Med. 2015;192:843-852. [PMID: 26067395 DOI: 10.1164/rccm.201409-1698oc] [Cited by in Crossref: 38] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
81 Schmidt SL, Tayob N, Han MK, Zappala C, Kervitsky D, Murray S, Wells AU, Brown KK, Martinez FJ, Flaherty KR. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014;145:579-85. [PMID: 24231810 DOI: 10.1378/chest.13-0844] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 8.5] [Reference Citation Analysis]
82 Lancaster L, Goldin J, Trampisch M, Kim GH, Ilowite J, Homik L, Hotchkin DL, Kaye M, Ryerson CJ, Mogulkoc N, Conoscenti CS. Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respir Med J 2020;14:22-31. [PMID: 33088361 DOI: 10.2174/1874306402014010022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Yagi K, Asakura T, Namkoong H, Suzuki S, Asami T, Okamori S, Kusumoto T, Funatsu Y, Kamata H, Nishimura T, Ishii M, Betsuyaku T, Hasegawa N. Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease. BMC Pulm Med 2018;18:114. [PMID: 30005658 DOI: 10.1186/s12890-018-0686-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
84 Kundu S, Mitra S, Ganguly J, Mukherjee S, Ray S, Mitra R. Spectrum of diffuse parenchymal lung diseases with special reference to idiopathic pulmonary fibrosis and connective tissue disease: An eastern India experience. Lung India 2014;31:354-60. [PMID: 25378843 DOI: 10.4103/0970-2113.142115] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
85 Briand J, Behal H, Chenivesse C, Wémeau-Stervinou L, Wallaert B. The 1-minute sit-to-stand test to detect exercise-induced oxygen desaturation in patients with interstitial lung disease. Ther Adv Respir Dis 2018;12:1753466618793028. [PMID: 30091679 DOI: 10.1177/1753466618793028] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
86 Richman PS, Richman DC. The role of cardiopulmonary exercise testing in perioperative risk assessment. Int Anesthesiol Clin 2021;59:22-9. [PMID: 33252572 DOI: 10.1097/AIA.0000000000000306] [Reference Citation Analysis]
87 Houchen-Wolloff L, Evans RA. Unravelling the mystery of the 'minimum important difference' using practical outcome measures in chronic respiratory disease. Chron Respir Dis 2019;16:1479973118816491. [PMID: 30789024 DOI: 10.1177/1479973118816491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
88 Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA 2018;319:2299-307. [PMID: 29800034 DOI: 10.1001/jama.2018.6129] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 21.3] [Reference Citation Analysis]
89 Manzetti GM, Hosein K, Cecchini MJ, Kwan K, Abdelrazek M, Zompatori M, Rogliani P, Mura M. Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. BMC Pulm Med 2021;21:396. [PMID: 34863146 DOI: 10.1186/s12890-021-01753-7] [Reference Citation Analysis]
90 Swigris JJ, Han M, Vij R, Noth I, Eisenstein EL, Anstrom KJ, Brown KK, Fairclough D. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med 2012;106:1447-55. [PMID: 22801586 DOI: 10.1016/j.rmed.2012.06.018] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
91 Duarte AC, Cordeiro A, Fernandes BM, Bernardes M, Martins P, Cordeiro I, Santiago T, Seixas MI, Ribeiro AR, Santos MJ. Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 2019;38:2001-9. [PMID: 31016581 DOI: 10.1007/s10067-019-04557-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
92 Holland AE, Dowman L, Fiore J Jr, Brazzale D, Hill CJ, McDonald CF. Cardiorespiratory responses to 6-minute walk test in interstitial lung disease: not always a submaximal test. BMC Pulm Med 2014;14:136. [PMID: 25113781 DOI: 10.1186/1471-2466-14-136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
93 Keyser RE, Woolstenhulme JG, Chin LM, Nathan SD, Weir NA, Connors G, Drinkard B, Lamberti J, Chan L. Cardiorespiratory function before and after aerobic exercise training in patients with interstitial lung disease. J Cardiopulm Rehabil Prev 2015;35:47-55. [PMID: 25313451 DOI: 10.1097/HCR.0000000000000083] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]
94 Vega-Olivo M, Criner GJ. Idiopathic pulmonary fibrosis: A guide for nurse practitioners. Nurse Pract 2018;43:48-54. [PMID: 29465476 DOI: 10.1097/01.NPR.0000531121.07294.36] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
95 Swigris JJ, Esser D, Conoscenti CS, Brown KK. The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. Health Qual Life Outcomes 2014;12:124. [PMID: 25138056 DOI: 10.1186/s12955-014-0124-1] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 6.0] [Reference Citation Analysis]
96 Storer TW, Miciek R, Travison TG. Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl. 2012;14:204-221. [PMID: 22367184 DOI: 10.1038/aja.2011.104] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
97 Bassi I, Guerrieri A, Carpano M, Gardini A, Prediletto I, Polastri M, Curtis JR, Nava S. Feasibility and efficacy of a multidisciplinary palliative approach in patients with advanced interstitial lung disease. A pilot randomised controlled trial. Pulmonology 2021:S2531-0437(21)00223-3. [PMID: 34969647 DOI: 10.1016/j.pulmoe.2021.11.004] [Reference Citation Analysis]
98 Gupta S, Padhan P, Subhankar S, Singh P. Cardiovascular complications in patients with interstitial lung disease and their correlation with 6-minute walk test and spirometry: A single-center study. J Family Med Prim Care 2021;10:3330-5. [PMID: 34760753 DOI: 10.4103/jfmpc.jfmpc_350_21] [Reference Citation Analysis]
99 Kang M, Marts L, Kempker JA, Veeraraghavan S. Minimal clinically important difference in idiopathic pulmonary fibrosis. Breathe (Sheff) 2021;17:200345. [PMID: 34295421 DOI: 10.1183/20734735.0345-2020] [Reference Citation Analysis]
100 Kato D, Dobashi K, Fueki M, Tomioka S, Yamada H, Fueki N. Short-term and long-term effects of a self-managed physical activity program using a pedometer for chronic respiratory disease: a randomized controlled trial. J Phys Ther Sci 2017;29:807-12. [PMID: 28603350 DOI: 10.1589/jpts.29.807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
101 Behr J. The diagnosis and treatment of idiopathic pulmonary fibrosis. Dtsch Arztebl Int 2013;110:875-81. [PMID: 24529303 DOI: 10.3238/arztebl.2013.0875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
102 Keyser RE, Christensen EJ, Chin LM, Woolstenhulme JG, Drinkard B, Quinn A, Connors G, Weir NA, Nathan SD, Chan LE. Changes in fatigability following intense aerobic exercise training in patients with interstitial lung disease. Respir Med 2015;109:517-25. [PMID: 25698651 DOI: 10.1016/j.rmed.2015.01.021] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
103 Swiatek KM, Lester C, Ng N, Golia S, Pinson J, Grinnan D. Impact of Face Masks on 6-Minute Walk Test in Healthy Volunteers. Pulm Circ 2021;11:2045894020988437. [PMID: 33532062 DOI: 10.1177/2045894020988437] [Reference Citation Analysis]
104 Lancaster LH. Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidiscip Respir Med 2018;13:45. [PMID: 30559965 DOI: 10.1186/s40248-018-0158-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
105 Mugii N, Someya F. Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies. Rheumatol Int 2018;38:1443-8. [PMID: 29761224 DOI: 10.1007/s00296-018-4050-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Puxeddu E, Rogliani P. Prognostic scoring systems for clinical course and survival in idiopathic pulmonary fibrosis. World J Respirol 2016; 6(1): 14-23 [DOI: 10.5320/wjr.v6.i1.14] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
107 Zhou M, Zhang H, Li F, Yu Z, Yuan C, Oliver B, Li J. Pulmonary Daoyin as a traditional Chinese medicine rehabilitation programme for patients with IPF: A randomized controlled trial. Respirology 2021;26:360-9. [PMID: 33164264 DOI: 10.1111/resp.13972] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Schrover R, Evans K, Giugliani R, Noble I, Bhattacharya K. Minimal clinically important difference for the 6-min walk test: literature review and application to Morquio A syndrome. Orphanet J Rare Dis 2017;12:78. [PMID: 28441951 DOI: 10.1186/s13023-017-0633-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
109 Hervier B, Uzunhan Y. Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment. Front Med (Lausanne) 2019;6:326. [PMID: 32010700 DOI: 10.3389/fmed.2019.00326] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
110 Tan VZ, Lee MQ, Wong DL, Huang KS, Chan MY, Yan CC, Yeung MT. The Chinese (Mandarin) instructions of the 6-minute walk test: A validation study. Hong Kong Physiother J 2021;41:45-53. [PMID: 34054256 DOI: 10.1142/S1013702521500049] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Putman RK, Rosas IO, Hunninghake GM. Genetics and early detection in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2014;189:770-8. [PMID: 24547893 DOI: 10.1164/rccm.201312-2219PP] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 6.6] [Reference Citation Analysis]
112 Tandon PK, Kakkis ED. The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases. Orphanet J Rare Dis 2021;16:183. [PMID: 33874971 DOI: 10.1186/s13023-021-01805-5] [Reference Citation Analysis]
113 Celli B, Tetzlaff K, Criner G, Polkey MI, Sciurba F, Casaburi R, Tal-Singer R, Kawata A, Merrill D, Rennard S; COPD Biomarker Qualification Consortium. The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med. 2016;194:1483-1493. [PMID: 27332504 DOI: 10.1164/rccm.201508-1653oc] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
114 Baddini-Martinez JA. Six-minute walk test in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2018;44:257-8. [PMID: 30328922 DOI: 10.1590/S1806-37562018000040001] [Reference Citation Analysis]
115 Buzan MT, Pop CM. State of the art in the diagnosis and management of interstitial lung disease. Clujul Med 2015;88:116-23. [PMID: 26528058 DOI: 10.15386/cjmed-457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]